CTOs on the Move

Gene Link Inc

www.genelink.com

 
Gene Link Inc is a Hawthorne, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.genelink.com
  • 140 Old Saw Mill Riv Rd
    Hawthorne, NY USA 10532
  • Phone: 800.436.3546

Executives

Name Title Contact Details

Similar Companies

Molecular Therapeutics

Molecular Therapeutics, Inc. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adjuvance Technologies

Helping protect life through fundamental breakthroughs in vaccine adjuvant design and manufacturing.

Aptevo Therapeutics

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIRâ„¢ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients.

Pure Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE`s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate (SDC)- based antimicrobials, represent innovative advances in diverse markets and lead today`s global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area).

QurAlis

QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus our programs on tackling specific disease-causing mechanisms.